Infection medicines
WE AIM TO BUILD A LEADING FRANCHISE IN THE TREATMENT OF INFECTIOUS DISEASES BY INCREASING THE SALES OF THE MARKETED BRANDS SYNAGIS, MERREM AND FLUMIST AND BRINGING NEW PRODUCTS TO MARKET BY EXPLOITING OUR STRUCTURAL AND GENOMIC-BASED DISCOVERY TECHNOLOGIES AND OUR ANTIBODY PLATFORMS.
2007 IN BRIEF
- Merrem sales of $773 million, up 20%.
- Steady underlying growth for Merrem in the US (32%) and in Western Europe (20%).
- Since the acquisition of MedImmune in June, Synagis sales of $618 million and FluMist sales of $53 million.
- Acquistion of Arrow Therapeutics has added anti-viral capability.
- Acquistion of MedImmune has added infection-focused monoclonal antibody and vaccine technology.
- Work dedicated to finding a new treatment for tuberculosis continues at our R&D facility in Bangalore, India.
MARKETED PRODUCTS
Synagis (palivizumab) is a humanised monoclonal antibody (MAb) for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in paediatric patients at high risk of acquiring RSV disease (pneumonia and bronchiolitis).
Merrem/Meronem1(meropenem) is an intravenous carbapenem anti-bacterial for the treatment of serious, hospital-acquired infections.
FluMist (influenza virus vaccine live, intranasal) is a live, attenuated vaccine for the prevention of disease caused by influenza A and B viruses in healthy children and adolescents, two to 17 years of age, and healthy adults, 18 to 49 years of age.
1Licensed from Dainippon Sumitomo Pharma Co., Ltd.
